^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TP73 (Tumor Protein P73)

    i
    Other names: TP73, Tumor Protein P73, P73, P53-Like Transcription Factor 3, P53-Related Protein 3
    1m
    ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. (PubMed, Cell Rep Med)
    Genetic or pharmacological inhibition of the transcriptional activity of CEBPA with guanfacine reduces ΔNp73 levels and restores drug sensitivity involving ferroptosis-mediated cell death, acting synergistically with venetoclax. Our study sheds light on a previously undercharacterized poor-risk subgroup of AML, which may support patient stratification and inform treatment considerations.
    Journal
    |
    TP53 (Tumor protein P53) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • TP73 (Tumor Protein P73)
    |
    TP53 mutation
    |
    Venclexta (venetoclax)
    3ms
    Multi-omics elucidation of KDM5C, KDM6A, and KMT2B roles in cancer epigenetic dysregulation and transcriptional reprogramming. (PubMed, Commun Biol)
    Finally, integrative analyzes demonstrated strong correlations between promoter accessibility, transcription factor occupancy, and gene expression, and uncovered cooperation between epigenetic and genetic drivers. Together, these findings reveal context-dependent functional hierarchies among HMEs and underscore the necessity of multi-layered analyses to resolve the complexity of epigenetic regulation in cancer.
    Journal
    |
    KDM6A (Lysine Demethylase 6A) • KDM5C (Lysine Demethylase 5C) • GATA2 (GATA Binding Protein 2) • KMT2B (Lysine Methyltransferase 2B) • TP73 (Tumor Protein P73) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit) • PATZ1 (POZ/BTB And AT Hook Containing Zinc Finger 1) • HOXA10 (Homeobox A10)
    4ms
    Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. (PubMed, Cancer Res)
    Patients with acquired resistance to sotorasib may benefit from follow-up monotherapy with CDK12/13 inhibitors, the first of which recently entered clinical trials. Targeting CDK12/13 thus offers a promising strategy to overcome or prevent resistance to KRAS inhibitors.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CDK12 (Cyclin dependent kinase 12) • TP73 (Tumor Protein P73)
    |
    KRAS mutation
    |
    Lumakras (sotorasib)
    4ms
    DNA methylation profiles and cancer in children conceived after assisted reproductive technology. (PubMed, Clin Epigenetics)
    This study indicates that relatively few genes that are known targets for somatic/germline mutation in cancer experience DNA methylation changes in individuals conceived through ART. By contrast, DNA methylation disturbances reported in leukemia represent more than one-third of those associated with ART conception, thus raising the question of their role in leukemia risk in ART-conceived individuals. Among them, a few critical genes such as TP73, a tumor suppressor, were shown to be targeted for hypermethylation, both in ART and leukemia, warranting further investigation.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • TP73 (Tumor Protein P73) • CHD2 (Chromodomain Helicase DNA Binding Protein 2)
    6ms
    Harnessing TP73‑targeted nintedanib: A novel strategy to halt triple‑negative breast cancer via p53‑PPARα/PI3K‑Akt pathway suppression. (PubMed, Int J Oncol)
    In conclusion, nintedanib exerts potent anti‑TNBC effects by modulating TP73, disrupting oncogenic signaling via the p53‑PPARα/PI3K‑Akt axis, and attenuating EMT‑associated transcription factors. These findings highlight its potential as a promising targeted therapy for TNBC, warranting further clinical exploration.
    Journal
    |
    TP73 (Tumor Protein P73) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    nintedanib
    8ms
    Expression of DNA repair and cell cycle control genes in HPV infection. (PubMed, Vavilovskii Zhurnal Genet Selektsii)
    In the control, a correlation between the transcription levels of genes involved in the functioning of the p53 protein was revealed. An increase in viral load during HPV infection is associated with a change in the coexpression of DNA repair and cell cycle control genes.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ERCC2 (Excision repair cross-complementation group 2) • CHEK2 (Checkpoint kinase 2) • SIRT1 (Sirtuin 1) • TP73 (Tumor Protein P73) • APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1)
    10ms
    Effects of n-Myc and c-Myc on the expression of p53 family members and their transcriptional targets in human neuroblastoma cells. (PubMed, Biochem Biophys Res Commun)
    Our results showed that despite the same target, MDM2, these compounds displayed different cytotoxic effects and synergy with doxorubicin on two widely used NB cell lines, IMR-32 and SH-SY5Y that vary in the amount of MDM2 expression. Collectively, our results suggest that except Nutlin-3a, the other two inhibitors, Mel23 and SP-141, employ additional Mdm2-independent mechanisms of cytotoxicity in NB cells that warrants further investigation.
    Journal
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MDM2 (E3 ubiquitin protein ligase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • TP63 (Tumor protein 63) • TP73 (Tumor Protein P73)
    |
    TP53 mutation
    |
    doxorubicin hydrochloride
    10ms
    Long Non-Coding TP73-AS1: A Potential Biomarker and Therapeutic Target in Cancer. (PubMed, Int J Mol Sci)
    Subsequently, we introduce the role of TP73-AS1 in common malignant tumors such as gastric cancer (GC), lung cancer, colorectal cancer (CRC), etc. Last, emphasis is given to the potential clinical value of TP73-AS1, especially as single nucleotide polymorphisms of this lncRNA are associated with the risk of GC and CRC. Therefore, this review highlights the significance of TP73-AS1 as a novel biomarker and therapeutic target.
    Review • Journal
    |
    TP73 (Tumor Protein P73)
    10ms
    Transcription Factor p73 Is a Predictor of Platinum Resistance and Promotes Aggressive Epithelial Ovarian Cancers. (PubMed, Int J Mol Sci)
    In contrast, p73 deletion in A2780cis led to reduced proliferation and enhanced sensitivity to cisplatin, along with DNA double-strand break accumulation, G2/M cell cycle arrest, and increased apoptosis. We conclude that p73 is a predictor of platinum resistance. p73 can be exploited for targeted ovarian cancer therapy.
    Journal
    |
    TP73 (Tumor Protein P73)
    |
    cisplatin
    10ms
    lncRNAs and circRNAs: Emerging Players in Pediatric Medulloblastoma Pathology. (PubMed, Curr Med Chem)
    While these strategies hold promise, major hurdles include functional redundancy, optimizing in vivo delivery, and mitigating off-target effects. By detailing these challenges and outlining future research directions, this review underscores the revolutionary potential of ncRNA-focused diagnostics and therapies for managing pediatric medulloblastomas, offering new paths for improving survival outcomes and quality of life in affected children.
    Journal
    |
    HOTAIR (HOX Transcript Antisense RNA) • TP73 (Tumor Protein P73)
    11ms
    Unveiling racial disparities in prostate cancer using an integrative genomic and transcriptomic analysis. (PubMed, Cell Insight)
    These genetic variations likely contribute to disease progression and therapy response disparities. This study highlights the importance of considering genetic and epigenetic variations in developing tailored therapeutic approaches to improve treatment efficacy and reduce mortality rates across diverse populations.
    Journal
    |
    HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) • TP73 (Tumor Protein P73)
    12ms
    Molecular profiling of breast cancer methylation pattern in triple negative versus non- triple negative breast cancer. (PubMed, Sci Rep)
    The hypermethylation of BRCA1 and GSTP were independent predictors of DFS, while PTEN hypermethylation was an independent predictor of OS in the TNBC cohort. The identification of hypermethylated genes, such as BRCA1, CCND2, CDH1, ESR1, GSTP, RASSF1, SLIT2, MGMT, and PTEN may serve as potential biomarkers or therapeutic targets for TNBC.
    Journal • BRCA Biomarker
    |
    ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDH1 (Cadherin 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CCND2 (Cyclin D2) • RASSF1 (Ras Association Domain Family Member 1) • SLIT2 (Slit Guidance Ligand 2) • TP73 (Tumor Protein P73) • CCNA1 (Cyclin A1) • HIC1 (HIC ZBTB Transcriptional Repressor 1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • PYCARD (PYD And CARD Domain Containing) • TNFRSF10C (TNF Receptor Superfamily Member 10c)